Please assess the completion status of the following clinical trial:

Trial Title: Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy term infant 21-90 days of age~2. Birth weight ≥2500 g~3. Exclusively breastfed (to reduce variability in the intestinal microflora attributable to dietary variations)~4. With colic symptoms (\>3 hours of crying on \>3 days per week) with debut 10 ± 5 days before enrollment~5. Gestational age between 37 and 42 weeks~6. Apgar score higher than 7 at 5 minutes~7. Written informed consent from a parent~Exclusion Criteria:~1. Any chronic illness or gastrointestinal disorder as judged by the pediatrician~2. Any history of antibiotic treatment or probiotic supplementation~3. Failure to obtain a written consent by parent/legal guardian~4. Participation in other clinical trials~5. Infants with acute illness~6. Subjects with allergies or family history of allergies to any of the ingredients of the study product or placebo

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Biogaia L. reuteri DSM 17938 (Type: EXPERIMENTAL): Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10\^8 cfu),5 drops, once per day for 21 days.
- Probiotic Placebo (Type: PLACEBO_COMPARATOR): Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).